Baxter hails impact and progress of haemophilia therapy Advate

Baxter has underlined the ongoing market impact and regulatory progress of Advate, its groundbreaking recombinant treatment for patients with haemophilia A.

The product – which is the first of its kind to feature no human or animal protein additives – continues to be the most prescribed full-length recombinant FVIII worldwide, with more than ten years of real-world experience and over 17 billion units distributed.

In the last few months, the firm received EU regulatory approval for a new manufacturing facility in Singapore for the production of Advate and other recombinant products, while the drug was recently named the national preferred rFVIII therapy of choice in Australia.

These developments, in addition to recent regulatory approvals in Turkey and Russia, have helped Baxter to strengthen the status of its haemophilia portfolio.

Dr Ludwig Hantson, president of Baxter BioScience, said: "These important achievements will allow us to build upon our global leadership and drive continued growth across our haemophilia franchise, reaching patients in both large and established markets, as well as emerging markets."

This comes after the firm reported data from a four-year outcomes registry of haemophilia A patients earlier this year that showed the long-term benefits that Advate can offer.